A new pragmatic design for dose escalation in phase 1 clinical trials using an adaptive continual reassessment method
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A new pragmatic design for dose escalation in phase 1 clinical trials using an adaptive continual reassessment method
Authors
Keywords
Adaptive design, Bayesian adaptive, Simulation, 3 + 3 design, Maximal tolerated dose, Dose-finding, CRM, Model-based design, Rule-based design
Journal
BMC CANCER
Volume 19, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-06-26
DOI
10.1186/s12885-019-5801-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Time-to-event model-assisted designs for dose-finding trials with delayed toxicity
- (2019) Ruitao Lin et al. BIOSTATISTICS
- Homeostatic Restoration of Desmoplastic Stroma Rather Than Its Ablation Slows Pancreatic Cancer Progression
- (2015) Fieke E.M. Froeling et al. GASTROENTEROLOGY
- Scientific Review of Phase I Protocols With Novel Dose-Escalation Designs: How Much Information Is Needed?
- (2015) Alexia Iasonos et al. JOURNAL OF CLINICAL ONCOLOGY
- bcrm: Bayesian Continual Reassessment Method Designs for Phase I Dose-Finding Trials
- (2015) Michael Sweeting et al. Journal of Statistical Software
- Adaptive Dose-Finding Studies: A Review of Model-Guided Phase I Clinical Trials
- (2014) Alexia Iasonos et al. JOURNAL OF CLINICAL ONCOLOGY
- Activated Pancreatic Stellate Cells Sequester CD8+ T Cells to Reduce Their Infiltration of the Juxtatumoral Compartment of Pancreatic Ductal Adenocarcinoma
- (2013) Abasi Ene–Obong et al. GASTROENTEROLOGY
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interplay of priors and skeletons in two-stage continual reassessment method
- (2012) Alexia Iasonos et al. STATISTICS IN MEDICINE
- Retinoic Acid–Induced Pancreatic Stellate Cell Quiescence Reduces Paracrine Wnt–β-Catenin Signaling to Slow Tumor Progression
- (2011) Fieke E.M. Froeling et al. GASTROENTEROLOGY
- Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
- (2011) Daniel D. Von Hoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Bayesian Adaptive Dose-Finding Studies with Delayed Responses
- (2010) Haoda Fu et al. Journal of Biopharmaceutical Statistics
- Randomized Phase II Trial of All-Trans-Retinoic Acid With Chemotherapy Based on Paclitaxel and Cisplatin As First-Line Treatment in Patients With Advanced Non–Small-Cell Lung Cancer
- (2010) Oscar Arrieta et al. JOURNAL OF CLINICAL ONCOLOGY
- Continual Reassessment and Related Dose-Finding Designs
- (2010) John O’Quigley et al. STATISTICAL SCIENCE
- A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies
- (2008) Alexia Iasonos et al. Clinical Trials
- Shortening the Timeline of Pediatric Phase I Trials: The Rolling Six Design
- (2008) Jeffrey M. Skolnik et al. JOURNAL OF CLINICAL ONCOLOGY
- Critical aspects of the Bayesian approach to phase I cancer trials
- (2008) Beat Neuenschwander et al. STATISTICS IN MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More